These trials confirmed clinically sizeable pharmacokinetic interactions [7] characterized by a decrease in the clearance of the anticancer drug and hence increased publicity. The interpretation of subsequent phase II and III clinical trials was complicated because it was not possible to administer the same dose of chemotherapy in the presence https://johna221oak5.bcbloggers.com/profile